BillionToOne, Inc. (BLLN) stock
BLLNNasdaqServices-Medical LaboratoriesFiscal year ends December 31
$97.50+1.19 (+1.24%)
Close on Nov 17, 2026Market cap $4.60BP/E –Yield –
BillionToOne r&d expenses
Research and development expenses are spending on new products and technology.
BillionToOne's R&D Expenses for the twelve months ending Sep 30, 2026 was $66.47M, up 44.1% year over year. For fiscal 2025 it was $49.38M, up 34.9% from the year before.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $49.38M | +34.9% |
| FY2024 | Dec 31, 2024 | $36.60M | +63.3% |
| FY2023 | Dec 31, 2023 | $22.41M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $20.22M | +56.1% |
| Q2 FY2026 | Jun 30, 2026 | $17.32M | +47.3% |
| Q1 FY2026 | Mar 31, 2026 | $14.69M | +40.9% |
| Q4 FY2025 | Dec 31, 2025 | $14.25M | +29.6% |
| Q3 FY2025 | Sep 30, 2025 | $12.95M | +35.6% |
| Q2 FY2025 | Jun 30, 2025 | $11.75M | – |
| Q1 FY2025 | Mar 31, 2025 | $10.43M | – |
| Q4 FY2024 | Dec 31, 2024 | $11.00M | – |
| Q3 FY2024 | Sep 30, 2024 | $9.55M | – |
See a number that looks wrong?